Page 26 - Pharma Industry

Coronavirus outbreak: Don't panic over supplies, says pharma industry

Sun Pharma's Dilip Shanghvi said the industry and government were working closely to reduce dependence on one country

Indian pharma industry needs to adopt digital technologies, says EY report

India is the largest provider of generic drugs globally, fulfilling about 40 per cent of the generics demand in the US and roughly 25 per cent of all medicines in UK

Pharma industry poised to beat FY19 exports despite strict US regulations

April-December exports rise 11.5%; estimates peg FY20 numbers at $22 billion

Pharma companies can draw $30 bn revenue from US market by tapping 10 drugs

Despite having good demand from across the markets, primarily due to lower prices and easy availability, India controls only 2.4 per cent of global pharma exports

Tipping point: Should you bet on the revival of pharmaceutical funds?

Whenever the domestic economy is not doing well, smart money shifts to export-oriented sectors like pharma

Pharma industry considering 'ethics inspectors' to ensure better compliance

Pharma players to meet DoP to discuss suggestions around implementing ethical marketing practices code

Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf

Repositioning an old brand helps expand the footprint, say analysts

In a booster dose, pharma industry gets 'green' signal in New Year

Drug makers allowed to tweak product mix or quantity without fresh environment clearance until effluent load is same

Pharma firms plan awareness drive to battle cancer scare in antacid

Indian companies have also been hit in their global business.

Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad

According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact

China opens public hospitals for Dr Reddy's Laboratories generic drugs

First Indian firm to get contract for supplying generic schizophrenia drug to public hospitals there

Unichem gets USFDA approval for high blood pressure drug Chlorthalidone

Unichem said the product will be commercialised from its Ghaziabad plant

Natco Pharma's API facility near Hyderabad gets 6 USFDA observations

The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust

Aurobindo to Jubilant Life Sciences, drug makers face USFDA heat

Some of the inspections have not yet received a final classification, which raises the potential for OAIs

Bulk drug exports rise as Indian makers cash in on China's regulatory woes

Iran emerged as a major destination in FY19 with 68% growth after registering negative growth in FY17 and FY18

From Lupin to Dr. Reddy's, year may end on a good note for pharma firms

During the previous quarter too, the Indian drug firms had reported a better than expected performance in the US

Drugmakers make lowest return on R&D investments in 9 years: Deloitte

LONDON (Reuters) - The cost of developing a new drug has nearly doubled since 2010 and the world's 12 biggest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte.

Hypertension drug recall by USFDA shot in the arm for some drug majors

The recall was due to an impurity (N-Nitrosodimethylamine or NDMA) which was found in the recalled products that include valsartan and its combinations

Falling rupee to boost pharma top lines, margins in Q2: India Ratings

However, drug firms focussed on domestic market would post muted growth in Q2FY19 on a year-on-year basis

USFDA generic guidance to help local pharma formulators with ANDA approvals

The recent guidance from the US Food & Drug Administration (USFDA) on complex generics is expected to provide more clarity to US-focused Indian pharmaceutical formulators in preparing and submitting abbreviated new drug applications (ANDAs), says a report. This will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend report by India Ratings. The current guidance dated October 9 is specific to complex transdermal and topical products. The agency in its mid-year FY19 pharma outlook had identified the lack of scientific and regulatory clarity about complex drugs as one of the key hurdles for approvals of complex products. Indian pharmaceutical formulators have indicated low double-digit pricing erosion for their base portfolio at end-FY18 and were exiting highly generic commercially unviable products and pruning R&D pipeline. The regulatory clarity will benefit formulators such as Lupin ...